Fuse Medical, Inc. announced the initial launch of FuseChoice and FuseChoice Plus Amniotic & Umbilical Membranes, and FuseChoice Plus Amniotic Joint Cushioning Fluid, the latest additions to a comprehensive line of biologics product offerings. FuseChoice Single Layer Amniotic Membrane, FuseChoice Plus Multi-Layer Amniotic Membrane, and FuseChoice Max Umbilical Membrane may be used as an anatomical barrier in numerous clinical applications. The natural properties of amniotic tissue help provide mechanical protection to damaged tissue, while the proprietary process retains essential nutrient-rich growth factors. The FuseChoice Plus AF Amniotic Joint Cushioning Fluid is an all-natural liquid matrix allograft derived from amniotic fluid. The cushioning effect of amniotic fluid in utero shields the fetus from outside pressures, acting as a shock absorber. It principally functions to cushion surface articulation within the joint capsule to provide shock absorption, lubrication, and joint stability by harnessing the natural cushioning properties of amniotic fluid to deliver the same support to joint capsules. Additional extensions to the Biologics and Regenerative Medicine portfolio in the first half of 2021 will include FuseChoice Derm Non-Fenestrated Dermal Matrix, FusePure Demineralized Bone Matrix, Strips and Cubes, and FuseTrilogy Viable Bone Matrix, an osteoconductive, osteoinductive & osteogenic DMSO-free bone void filler requiring no mixing preparation.